Immunohistochemical evaluation of HER-2/neu expression in infiltrating breast carcinoma: A study of reproducibility

Analytical and Quantitative Cytology and Histology

Volumn 24, Issue 1, 2002, Pages 54-62

  Santinelli, Alfredo ^a   Baccarini, Mariagrazia ^a   Colanzi, Paola ^a   Stramazzotti, Daniela ^a   Fabris, Guidalberto ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Breast cancer; HER 2 proto oncogene protein; HercepTest ; Reproducibility of results; TAB250

Indexed keywords

NEU DIFFERENTIATION FACTOR; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER INFILTRATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OBSERVER VARIATION; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; OBSERVER VARIATION; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 0036182017     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. The neu-protein and breast cancer
2. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
3. HER-2/neu signal transduction in human breast and ovarian cancer
4. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
5. Studies of the Her2/neu proto-oncogene in human breast and ovarian cancer
6. ERB2 oncogene in human breast cancer and its clinical significance
7. Strategies for the analysis of oncogene overexpression: Studies of the neu oncogene in breast carcinoma
8. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
9. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization assays
10. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer
11. Prognostic importance of c-erbB-2 expression in breast cancer
12. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
13. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
14. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
15. C-erbB-2 expression and response to adjuvant therapy in women with node-positive breast cancer
16. Humanization of an anti-p 185HER2 antibody for human cancer therapy
17. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of Placlitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
18. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: A randomized, multinational controlled phase III trial
19. Experts debate value of HER2 testing methods
20. Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
21. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
22. HER-2/neu oncogene protein and prognosis in breast cancer
23. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up
24. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer
25. HER-2/neu amplification predicts poor survival in node-positive breast cancer
26. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
27. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer
28. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: Results from a randomized adjuvant treatment protocol
29. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy
30. c-erbB-2 amplification in node-negative human breast cancer
31. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer
32. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
33. Prognostic significance of c-erbB-2 expression in node negative breast cancer
34. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
35. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
36. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: A study of epidemiologic risk factors, histologic features, and prognosis
37. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB-2 in lymph node-negative breast cancer
38. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis
39. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer: Toronto Breast Cancer Study Group
40. Multivariate analysis of prognostic factors in lymph node negative breast cancer
41. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
42. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (> 10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy
43. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer
44. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
45. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
46. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with Tamoxifen (T) alone
47. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
48. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
49. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas
50. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma
51. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
52. C-erbB-2 immunostaining: Problems with interpretation
53. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry: A study of interlaboratory agreement